Previous close | 30.50 |
Open | 12.20 |
Bid | 8.70 |
Ask | 11.90 |
Strike | 880.00 |
Expiry date | 2024-06-21 |
Day's range | 9.75 - 12.20 |
Contract range | N/A |
Volume | |
Open interest | 95 |
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
First Quarter Results Show Revenue Decline but Strong Dupixent and Libtayo Sales Growth